J B CHEMICALS AND PHARMA

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company has, at its meeting held on November 12, 2019 inter-alia approved Buy-back of up to 29,54,545 fully paid-up Equity Shares of face value of Rs. 2/- each by the Company (representing 3.68% of the total paid-up equity shares of the Company) at a price of Rs. 440/- (Rupees four hundred forty Only) per Equity Share payable in cash for a total consideration not exceeding Rs.130 crores/- (Rupees one hundred thirty Crores only) (excluding transaction costs) which is 9.33% and 9.38% of the total

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has fixed Record Date as November 22, 2019 for the purpose of Buy-back.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 12, 2019, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2019.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 12, 2019 Unaudited Financial Results for the quarter ended on September 30, 2019. .

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 12, 2019 -Buy-back of Equity Shares by the Company.

Pranabh Dinesh Mody and Purvi Uday Asher has submitted to the Exchange a copy of Disclosures under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Detailed reason for resignation and confirmation by Independent director'.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Durga Dass Chopra as Independent Director of the company w.e.f. September 30, 2019.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'News about presence of NDMA in Ranitidine'.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Submission of application for re-classification under Regulation 31A of the Listing Regulations'.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

JB Chemicals & Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 23, 2019. Further, the company has informed the Exchange regarding voting results.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 23, 2019

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).'.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a revised press release dated August 13, 2019, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 13, 2019, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 13, 2019.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 23, 2019

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Notice of Annual General Meeting '.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has fixed Record Date as August 16, 2019 to ascertain eligibility of the beneficial owners/shareholders of the Company's shares to receive the dividend for FY 2018-19, if declared at the annual general meeting.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements), 2015 and Code for fair disclosure of UPSI'.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Successful US FDA inspection of new Solid Oral dosage forms formulations manufacturing facility at Panoli, Gujarat'.

The Exchange has sought clarification from JB Chemicals & Pharmaceuticals Limited with respect to recent news item captioned Lupin, Piramal Healthcare in Race for Stake in JB Chemicals. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. JB Chemicals & Pharmaceuticals Limited has submitted their response.

The Exchange has sought clarification from JB Chemicals & Pharmaceuticals Limited with respect to news item captioned ��Lupin, Piramal Healthcare in Race for Stake in JB Chemicals��. The response from the Company is awaited.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has submitted to the Exchange a copy of disclosure of related party transactions on consolidated basis for the the second half of the financial year 2018-19 of the Company.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Notice in respect of transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF).'.

The Exchange has sought clarification from JB Chemicals & Pharmaceuticals Limited with respect to recent news item captioned "JB Chemicals promoters to offload 57% stake". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. JB Chemicals & Pharmaceuticals Limited has submitted their response.

The Exchange has sought clarification from JB Chemicals & Pharmaceuticals Limited with respect to recent news item captioned "JB Chemicals promoters to offload 57% stake". The response from the company is awaited.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Intimation pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015'.

Requests received from certain promoter group members seeking re-classification of status as public under SEBI (Listing Obligations and Disclosure Requirements), 2015 as amended (��the said Regulations��)

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 21, 2019, recommended Final Dividend of Rs. 5 per equity share.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 21, 2019, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2019.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on May 21, 2019.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure of receipt of request from the promoter group member seeking re-classification of status as public'.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure of receipt of request from the promoter group member seeking re-classification of status as public'.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure of receipt of requests from the promoter group members seeking re-classification of status as public'.

The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019

The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 08, 2019, titled "Press Release".